Clinical Trials Directory

Trials / Completed

CompletedNCT00857402

Arginine as an Adjuvant Treatment Against Tuberculosis

Arginine Rich Food Supplementation as an Adjuvant Treatment Against Tuberculosis

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
180 (actual)
Sponsor
Linkoeping University · Other Government
Sex
All
Age
15 Years – 60 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study was to investigate if adjuvant treatment with arginine (the substrate for nitric oxide production) rich food supplements could improve clinical outcome in patients with smear positive tuberculosis by affecting nitric oxide production.

Detailed description

Tuberculosis (TB) is disease of increased global public health importance. Because of emerging multi drug resistance and the long treatment duration there is a need to optimize the current chemotherapy. Host immunity is important in determining the susceptibility and outcome of disease as could be exemplified by co infection with HIV which dramatically increases the risk to develop TB. Previous results from our group and others show that nitric oxide produced by activated macrophages from arginine might be important to control the disease. However, the relative importance of nitric oxide in human TB has been debated. In a previous study in Gondar, Ethiopia, we observed an effect of adjuvant treatment with arginine capsules on sputum smear conversion and reduction of cough. In this study we wanted to test the hypothesis based on previous observations that an arginine rich food supplementation might enhance clinical improvement in patients with smear positive tuberculosis and if this effect could be due to increased nitric oxide production.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTPeanuts30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
DIETARY_SUPPLEMENTDaboqolo30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.

Timeline

Start date
2004-02-01
Primary completion
2006-12-01
Completion
2006-12-01
First posted
2009-03-06
Last updated
2009-03-06

Locations

1 site across 1 country: Ethiopia

Source: ClinicalTrials.gov record NCT00857402. Inclusion in this directory is not an endorsement.